Article Data

  • Views 966
  • Dowloads 127

Original Research

Open Access

Knockdown of CUEDC1 restrains the growth and migration of hepatocellular carcinoma cells through affecting the TβRI/Smad signaling pathway

  • Jin Wang1
  • Zhenglan Cao2
  • Kehong Chen3,*,

1The Second Clinical College, Chongqing Medical University, 400010 Chongqing, China

2Department of Clinical Laboratory, Sichuan Provincial People’s Hospital Jinniu Hospital, 610036 Chengdu, Sichuan, China

3Department of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, 400010 Chongqing, China

DOI: 10.22514/jomh.2024.061 Vol.20,Issue 4,April 2024 pp.127-132

Submitted: 25 February 2024 Accepted: 02 April 2024

Published: 30 April 2024

*Corresponding Author(s): Kehong Chen E-mail: chenkehong@stu.cqmu.edu.cn

Abstract

Hepatocellular carcinoma (HCC), as one usual tumor, and owns the significant mortality rates. The involvement of the coupling of ubiquitin conjugation to endoplasmic reticulum degradation (CUE) domain containing 1 (CUEDC1) in cancer progression, either facilitating or inhibiting, has been documented in various cancers. Nevertheless, the regulatory role of CUEDC1 in HCC progression holds unclear. This work aims to elucidate the impact of CUEDC1 on HCC progression. Analysis using the Gene Expression Profiling Interactive Analysis (GEPIA) online database revealed elevated expression of CUEDC1 in liver hepatocellular carcinoma (LIHC) tissues. Subsequently, in HCC cell lines, the elevated CUEDC1 protein expression was confirmed. Silencing CUEDC1 was found to restrain tumor growth in HCC, alongside attenuating cell migration and invasion. Notably, knockdown of CUEDC1 was determined to activate the transforming growth factor-β receptor I (TβRI)/Smad signaling pathway. In conclusion, this study demonstrates that CUEDC1 knockdown restrained the growth and migration of HCC cells under affecting the TβRI/Smad signaling pathway. These findings suggest CUEDC1 could be a helpful target for HCC improvement.


Keywords

CUEDC1; Migration; Hepatocellular carcinoma; The TβRI/Smad signaling pathway


Cite and Share

Jin Wang,Zhenglan Cao,Kehong Chen. Knockdown of CUEDC1 restrains the growth and migration of hepatocellular carcinoma cells through affecting the TβRI/Smad signaling pathway. Journal of Men's Health. 2024. 20(4);127-132.

References

[1] Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annual Review of Medicine. 2016; 67: 103–117.

[2] Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nature Reviews Disease Primers. 2021; 7: 6.

[3] Schütte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma—epidemiological trends and risk factors. Digestive Diseases. 2009; 27: 80–92.

[4] Bruix J, Qin S, Merle P, Granito A, Huang Y, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2017; 389: 56–66.

[5] Zhou H, Song T. Conversion therapy and maintenance therapy for primary hepatocellular carcinoma. BioScience Trends. 2021; 15: 155–160.

[6] Cui Y, Song Y, Yan S, Cao M, Huang J, Jia D, et al. CUEDC1 inhibits epithelial-mesenchymal transition via the TβRI/Smad signaling pathway and suppresses tumor progression in non-small cell lung cancer. Aging. 2020; 12: 20047–20068.

[7] Lopes R, Korkmaz G, Revilla SA, van Vliet R, Nagel R, Custers L, et al. CUEDC1 is a primary target of ERα essential for the growth of breast cancer cells. Cancer Letters. 2018; 436: 87–95.

[8] Zhuang WC, Wu QY, Meng FJ, Xu KL. Construction of a lentiviral vector carrying CUEDC1 gene and its effect on the proliferation and colony-formating ability of MOLT-4 Cells. Journal of Experimental Hematology. 2018; 26: 1257–1262. (In Chinese)

[9] Valastyan S, Weinberg R. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011; 147: 275–292.

[10] Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. Journal of Hematology and Oncology. 2022; 15: 129.

[11] Zhou C, Liu C, Liu W, Chen W, Yin Y, Li C, et al. SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway. Theranostics. 2020; 10: 4627–4643.

[12] Jiang H, Cao H, Ma N, Bao W, Wang J, Chen T, et al. Chromatin remodeling factor ARID2 suppresses hepatocellular carcinoma metastasis via DNMT1-Snail axis. Proceedings of the National Academy of Sciences. 2020; 117: 4770–4780.

[13] Liu D, Zhang T, Chen X, Zhang B, Wang Y, Xie M, et al. ONECUT2 facilitates hepatocellular carcinoma metastasis by transcriptionally upregulating FGF2 and ACLY. Cell Death & Disease. 2021; 12: 1113.

[14] Peng D, Fu M, Wang M, Wei Y, Wei X. Targeting TGF-β signal transduction for fibrosis and cancer therapy. Molecular Cancer. 2022; 21: 104.

[15] Bi J, Zheng J, Li Q, Bao S, Yu X, Xu P, et al. MicroRNA-181a-5p suppresses cell proliferation by targeting Egr1 and inhibiting Egr1/TGF-β/Smad pathway in hepatocellular carcinoma. The International Journal of Biochemistry & Cell Biology. 2019; 106: 107–116.

[16] Wan Z, Ma Y, Jiang T, Lin Y, Shi Y, Tan Y, et al. Six2 is negatively correlated with prognosis and facilitates epithelial-mesenchymal transition via TGF-β/Smad signal pathway in hepatocellular carcinoma. Hepatobiliary & Pancreatic Diseases International. 2019; 18: 525–531.

[17] Gao Z, Zhong M, Ye Z, Wu Z, Xiong Y, Ma J, et al. PAK3 promotes the metastasis of hepatocellular carcinoma by regulating EMT process. Journal of Cancer. 2022; 13: 153–161.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Directory of Open Access Journals (DOAJ) DOAJ is a unique and extensive index of diverse open access journals from around the world, driven by a growing community, committed to ensuring quality content is freely available online for everyone.

SCImago The SCImago Journal & Country Rank is a publicly available portal that includes the journals and country scientific indicators developed from the information contained in the Scopus® database (Elsevier B.V.)

Publication Forum - JUFO (Federation of Finnish Learned Societies) Publication Forum is a classification of publication channels created by the Finnish scientific community to support the quality assessment of academic research.

Scopus: CiteScore 0.7 (2022) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Norwegian Register for Scientific Journals, Series and Publishers Search for publication channels (journals, series and publishers) in the Norwegian Register for Scientific Journals, Series and Publishers to see if they are considered as scientific. (https://kanalregister.hkdir.no/publiseringskanaler/Forside).

Submission Turnaround Time

Conferences

Top